Table 1 Comparison of neutralization titers of patient sera analyzed by reporter assay and plaque reduction assay.
From: A high-throughput neutralizing antibody assay for COVID-19 diagnosis and vaccine evaluation
aSerum IDb | cPRNT50 | cmNG-NT50 | aSerum IDb | cPRNT50 | cmNG-NT50 |
|---|---|---|---|---|---|
1 (d1) | <20 | 35 | 32 (d9) | 640 | 762 |
2 (d5) | <20 | 38 | 33 (d8) | 320 | 846 |
3 (d4) | <20 | 50 | 34 (d14) | 800 | 873 |
4 (d5) | 40 | 58 | 35 (d16) | 1600 | 874 |
5 (d5) | 20 | 66 | 36 (d17) | 320 | 900 |
6 (d6) | 80 | 74 | 37 (d9) | 800 | 902 |
7 (d8) | 80 | 77 | 38 (d15) | 800 | 949 |
8 (d4) | 80 | 85 | 39 (d15) | 400 | 958 |
9 (d5) | 80 | 85 | 40 (d18) | 800 | 1016 |
10 (d1) | 80 | 95 | 41 (d28) | 1280 | 1072 |
11 (d6) | 80 | 96 | 42 (d12) | 800 | 1139 |
12 (NA) | 160 | 96 | 43 (d13) | 800 | 1145 |
13 (d6) | 40 | 111 | 44 (d14) | 800 | 1210 |
14 (d6) | 40 | 114 | 45 (d31) | 640 | 1213 |
15 (d1) | 80 | 115 | 46 (d8) | 800 | 1419 |
16 (d9) | 160 | 120 | 47 (d14) | 1600 | 1590 |
17 (d11) | 80 | 132 | 48 (d21) | 1600 | 1617 |
18 (d8) | 80 | 200 | 49 (d12) | 1600 | 2148 |
19 (NA) | 160 | 261 | 50 (NA) | 2560 | 2225 |
20 (d5) | 160 | 318 | 51 (d20) | 1600 | 2287 |
21 (d32) | 320 | 329 | 52 (d8) | 1600 | 2362 |
22 (d14) | 160 | 365 | 53 (d12) | 1600 | 2463 |
23 (d12) | 160 | 366 | 54 (d18) | 1600 | 2554 |
24 (d37) | 320 | 456 | 55 (d16) | 1600 | 2832 |
25 (NA) | 320 | 474 | 56 (d15) | 3200 | 3228 |
26 (d47) | 320 | 525 | 57 (d31) | 3200 | 4257 |
27 (d12) | 640 | 617 | 58 (NA) | 3200 | 5152 |
28 (d9) | 320 | 649 | 59 (d8) | 3200 | 5662 |
29 (d10) | 640 | 681 | 60 (NA) | 3200 | 5711 |
30 (d27) | 320 | 721 | 61–120 | <20 | <20 |
31 (d9) | 640 | 727 | Â | Â | Â |
